# US 10,245,308 B2 · Combination therapy utilizing P2X7 peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,245,308 B2
- Document ID: US10245308B2
- Status: Granted
- Kind: B2
- Application number: 15/399,337
- Filed: 2017-01-05
- Published: 2017-06-08
- Granted: 2019-04-02
- Earliest claimed: 2011-07-01
- Assignees: Biosceptre (Aust) Pty Ltd
- Applicants: Biosceptre (Aust) Pty Ltd
- Inventors: Julian Alexander Barden; Angus Gidley-Baird
- Web page: https://patentgrep.com/patent/US10245308B2

## CPC

- A61K 39/001102: {Receptors, cell surface antigens or cell surface determinants}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/575: {humoral response}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to producing humoral response to P2X7 receptors in individuals having cancer, and to minimizing the progression of cancer in said individuals.

## Claims

### Claim 1

A method for minimising the progression of cancer in an individual who has received a non-self antibody or antigen-binding fragment thereof for treatment of the cancer, the method including the step of:
forming an immune response to a P2X7 receptor in an individual who has received a non self antibody or antigen binding fragment thereof for treatment of the cancer by administering to the individual a P2X7 receptor fragment; wherein the fragment of the P2X7 receptor has an amino acid sequence selected from the group consisting of SEQ ID NO: 3 (KYYKENNVEKRTLIKVF), SEQ ID NO: 4 (GHNYTTRNILPGAGAKYYKENNVEK) and SEQ ID NO: 5 (GHNYTTRNILPGAGAKYYKENNVEKC);
wherein cancer in the individual has been reduced in size, mass or other physical measure by the administration of the non self antibody or antigen binding fragment thereof;
wherein the P2X7 receptor fragment is capable of inducing an antibody response in the individual,
thereby minimising the progression of cancer in the individual.

### Claim 2 (depends on 1)

The method of claim 1 wherein the individual does not have detectable non-self antibody or antigen-binding fragment thereof in circulation at the time of administering the P2X7 receptor fragment.

### Claim 3 (depends on 1)

The method of claim 1 wherein the reduction in size, mass or other physical measure results in the individual not having detectable cancer.

### Claim 4 (depends on 1)

The method of claim 1 wherein the individual has developed an immune response to the non-self antibody or antigen-binding fragment thereof.

### Claim 5 (depends on 1)

The method of claim 1 wherein the non-self antibody or antigen-binding fragment thereof binds to non-functional P2X7 receptor, but not to functional P2X7 receptor.

### Claim 6 (depends on 1)

The method of claim 1 wherein the non-self antibody or antigen-binding fragment thereof received by the individual for treatment of the cancer does not bind to a P2X7 receptor, or a fragment of a P2X7 receptor.

### Claim 7 (depends on 1)

The method of claim 1 wherein the P2X7 receptor fragment is provided in an initial administration to the individual, thereby forming a response that includes IgM production in the individual.

### Claim 8 (depends on 1)

The method of claim 1 wherein the P2X7 receptor fragment is provided in an initial administration to the individual, thereby forming a response that includes IgM production, and at a later time, in a further administration to the initial administration, thereby forming a response that includes IgG production.

### Claim 9

A process for forming a humoral immune response to cancer-associated P2X7 receptors in an individual who has received an anti-cancer antigen antibody for therapy of cancer, including the steps of:
forming an immune response in the individual by administering to the individual P2X7 receptor fragment wherein the fragment of the P2X7 receptor has an amino acid sequence selected from the group consisting of SEQ ID NO: 3 (KYYKENNVEKRTLIKVF), SEQ ID NO: 4 (GHNYTTRNILPGAGAKYYKENNVEK) and SEQ ID NO: 5 (GHNYTTRNILPGAGAKYYKENNVEKC);
wherein the P2X7 fragment is capable of inducing an antibody response in the individual,
wherein the immune response is formed in the individual at a time where anti-cancer antigen antibody administered for treatment of cancer is at a level or concentration that is substantially undetectable in the individual; and/or
the humoral immune response to cancer-associated P2X7 receptors is formed according to an immunisation schedule whereby the amount of antibody formed in the individual to cancer-associated P2X7 receptor is about 0.1 to 25 mg/kg individual.